Clinical trials · source year
25 selected, source-linked clinical trial records dated 2016. This is selective source coverage, not a complete timeline.
25 selected records.
8 connected profiles.
25 distinct public records.
Cited chronology
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00002779 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01309399 at 2026-07-30T21:34:56.507Z. Its registry update date was 2016-11-23, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01971242 at 2026-07-30T21:34:56.502Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02313220 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01444898 at 2026-07-30T21:36:16.906Z. Its registry update date was 2016-09-29, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT02478879 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-08-23, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02160990 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT01204476 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00033605 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-07-13, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01951651 at 2026-07-30T21:37:20.824Z. Its registry update date was 2016-05-16, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Lixisenatide
PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00241020 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01432405 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT01483651 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-03-29, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT01667900 at 2026-07-30T21:38:42.858Z. Its registry update date was 2016-03-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT01121939 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-02-05, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗